Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)? [Yahoo! Finance]
AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease [Yahoo! Finance]